This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
Name: Hyperfractionated total body irradiation
Description: Hyperfractionated TBI is administered by a linear accelerator at a dose rate of <20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).Type: RadiationRadiation, Thiotepa Radiation, Thiotepa & Radiation, Thiotepa & Cyclophosphamide
Name: Thiotepa
Description: Thiotepa 5 mg/kg IVType: DrugRadiation, Thiotepa Radiation, Thiotepa & Radiation, Thiotepa & Cyclophosphamide Clofarabine, Thiotepa Clofarabine, Thiotepa & Clofarabine, Thiotepa & Melphalan
Name: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg IVType: DrugRadiation, Thiotepa Radiation, Thiotepa & Radiation, Thiotepa & Cyclophosphamide
Name: Busulfan
Description: Busulfan (adult/ped dose)Type: DrugBusulfan, Fludarabine Busulfan, Fludarabine & Busulfan, Fludarabine & Melphalan
Name: Fludarabine
Description: Fludarabine 25 mg/m2 IVType: DrugBusulfan, Fludarabine Busulfan, Fludarabine & Busulfan, Fludarabine & Melphalan
Name: Melphalan
Description: Melphalan 70 mg/m2 IVType: DrugBusulfan, Fludarabine Busulfan, Fludarabine & Busulfan, Fludarabine & Melphalan Clofarabine, Thiotepa Clofarabine, Thiotepa & Clofarabine, Thiotepa & Melphalan
Name: Clofarabine
Description: Clofarabine 20-30 mg/m2 IVType: DrugClofarabine, Thiotepa Clofarabine, Thiotepa & Clofarabine, Thiotepa & Melphalan
Name: HPC(A) stem cell allograft
Description: All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.Type: ProcedureRadiation, Thiotepa Radiation, Thiotepa & Radiation, Thiotepa & Cyclophosphamide Busulfan, Fludarabine Busulfan, Fludarabine & Busulfan, Fludarabine & Melphalan Clofarabine, Thiotepa Clofarabine, Thiotepa & Clofarabine, Thiotepa & Melphalan
Name: Rituximab
Description: Rituximab 200 mg IV flat doseType: DrugRadiation, Thiotepa Radiation, Thiotepa & Radiation, Thiotepa & Cyclophosphamide Busulfan, Fludarabine Busulfan, Fludarabine & Busulfan, Fludarabine & Melphalan Clofarabine, Thiotepa Clofarabine, Thiotepa & Clofarabine, Thiotepa & Melphalan
Name: Rabbit antithymocyte globulin
Description: Rabbit antithymocyte globulin 2.5 mg/kg IVType: DeviceRadiation, Thiotepa Radiation, Thiotepa & Radiation, Thiotepa & Cyclophosphamide Busulfan, Fludarabine Busulfan, Fludarabine & Busulfan, Fludarabine & Melphalan Clofarabine, Thiotepa Clofarabine, Thiotepa & Clofarabine, Thiotepa & Melphalan
Description: The intervention will be considered unpromising if the rate of GVHD is greater than 40% and promising if the rate is 20% or less.
Measure: the number of incidences of grade 3-4 acute GVHD Time: 2 yearsAllocation: Non-Randomized
Parallel Assignment
There is one SNP
T351I mutation). --- T351I ---